Mereo Biopharma Group Plc ADR (NASDAQ: MREO) on Friday, plunged -5.59% from the previous trading day, before settling in for the closing price of $3.76. Within the past 52 weeks, MREO’s price has moved between $2.48 and $5.02.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -25.00% over the last five years. The company achieved an average annual earnings per share of -10.71%. With a float of $142.11 million, this company’s outstanding shares have now reached $154.73 million.
The firm has a total of 33 workers. Let’s measure their productivity. In terms of profitability, gross margin is -107.44%, operating margin of -10462.41%, and the pretax margin is -11633.65%.
Mereo Biopharma Group Plc ADR (MREO) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Mereo Biopharma Group Plc ADR is 8.16%, while institutional ownership is 62.54%. The most recent insider transaction that took place on Sep 13 ’24, was worth 253,454. In this transaction Chief Executive Officer of this company sold 60,046 shares at a rate of $4.22, taking the stock ownership to the 808,921 shares. Before that another transaction happened on Sep 12 ’24, when Company’s Chief Executive Officer sold 28,611 for $4.47, making the entire transaction worth $127,968. This insider now owns 868,967 shares in total.
Mereo Biopharma Group Plc ADR (MREO) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.71% per share during the next fiscal year.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Trading Performance Indicators
Mereo Biopharma Group Plc ADR (MREO) is currently performing well based on its current performance indicators. A quick ratio of 6.10 was reported for the most recent quarter.
Technical Analysis of Mereo Biopharma Group Plc ADR (MREO)
Analysing the last 5-days average volume posted by the [Mereo Biopharma Group Plc ADR, MREO], we can find that recorded value of 1.1 million was lower than the volume posted last year of 1.16 million. As of the previous 9 days, the stock’s Stochastic %D was 65.12%. Additionally, its Average True Range was 0.24.
During the past 100 days, Mereo Biopharma Group Plc ADR’s (MREO) raw stochastic average was set at 23.04%, which indicates a significant decrease from 57.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.98% in the past 14 days, which was higher than the 59.53% volatility it showed in the past 100 days.
Now, the first resistance to watch is $3.73. This is followed by the second major resistance level at $3.91. The third major resistance level sits at $4.07. If the price goes on to break the first support level at $3.39, it is likely to go to the next support level at $3.24. Now, if the price goes above the second support level, the third support stands at $3.06.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Key Stats
Market capitalization of the company is 549.29 million based on 155,146K outstanding shares. Right now, sales total 10,000 K and income totals -29,470 K. The company made 0 K in profit during its latest quarter, and -15,000 K in sales during its previous quarter.
